BioCentury
ARTICLE | Emerging Company Profile

Ixchelsis: Lasting longer

Ixchelsis targeting the oxytocin receptor to delay ejaculation more safely

September 9, 2013 7:00 AM UTC

Ixchelsis Ltd.'s oxytocin receptor antagonist could help treat premature ejaculation more safely than antidepressant SSRIs, which are prescribed off label for the condition.

Premature ejaculation is one of the most common male sexual dysfunctions and affects 20-30% of men worldwide. While definitions of the condition vary, there is general agreement that premature ejaculation occurs prior to or very soon after vaginal penetration, with concomitant sexual dissatisfaction and emotional distress...